The pharmaceutical industry is increasingly focused on developing pathway-based therapies for dry AMD, with promising treatments like ALK-001 and LBS-008 in trials, though a combination approach ...
AMD progresses through several stages, usually starting with dry AMD, which is the more common form of the condition. It advances to geographic atrophy (GA) in some cases. Both conditions damage ...
The trial found that LumiThera’s Valeda Light Delivery System significantly reduced the risk of vision loss and the start of geographic atrophy in dry AMD. More than 58% of the people studied ...